Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results
Sabino De Placido, Grazia Arpino(University of Naples Federico II), Marta Bonotto(University of Udine), Francesco Schettini(Target (United States)), Fabio Puglisi(University of Udine), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Vito Lorusso(Istituto Tumori Bari), Mariangela Ciccarese(Ospedale Vito Fazzi), Alessandra Fabi(Agostino Gemelli University Polyclinic), Mario Giuliano(Regione Campania), Daniela Cianniello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Claudia von Arx(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Bianca Maria Veneziani(Federico II University Hospital), Dario Bruzzese(University of Naples Federico II), Domenico Bilancia(Ospedale San Carlo), Giuseppe Buono(Federico II University Hospital), Andrea Michelotti(Ospedale Santa Chiara), Mariavittoria Locci, Roberta Caputo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ferdinando Riccardi(Fatebenefratelli Hospital)
Cited by 35
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|887
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724